The FDA is moving toward leadership changes in biologics and vaccines oversight, with sources telling Endpoints News that the agency is narrowing its search for a director of the Center for Biologics Evaluation and Research. The discussion follows the exit of controversial outgoing leader Vinay Prasad and could shape how biologics evidence standards are communicated. Separately, the FDA issued reminders to roughly 2,200 companies and sponsors after an internal review found that results were not reported for about 30% of registered clinical studies. The regulator’s push targets compliance with result-reporting obligations, aiming to improve data availability for patients and clinicians. For biotech developers, both moves affect the operational environment around evidence generation and transparency: leadership changes influence the tone of policy implementation, while result-reporting enforcement increases the reputational and regulatory risk for sponsors that fall behind. Taken together, the FDA messages signal heightened attention to governance of clinical evidence—particularly for biologics and other therapies that rely on registrational datasets.